FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of biochemistry, in particular to cyclic peptide, capable of inducing antibody response. Peptide consists of formula X2X3VGSNK-Z or X3VGSNKG-Z, where X2 represents E, G, Q or K, X3 represents D or N and Z represents agent, stabilising bent, present inside peptide sequence, with peptide being cyclised by covalent bonding of N-end amino acid with Z, where Z represents peptide fragment YNGK. Conjugate, containing said cyclic peptide, conjugated with immunogenic carrier molecule is also claimed. peptide and conjugate, which contains it, can be applied for production of medication or as vaccine against Alzheimer's disease. Methods of obtaining cyclic peptide and conjugate are also claimed.
EFFECT: invention makes it possible to obtain improved, less toxic vaccine against Alzheimer's disease.
8 cl, 11 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE COMPOUND, USEFUL FOR INHIBITING FORMATION OF AMYLOID PLAQUES | 2011 |
|
RU2588143C2 |
| EPITOPE, SPECIFIC TO AMYLOID BETA OLIGOMER AND ANTIBODIES | 2011 |
|
RU2644335C2 |
| PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE | 2013 |
|
RU2696566C2 |
| P-A-SUP35MC HYBRID GENE FOR ANALYSIS OF FACTORS REGULATING PRODUCTION, AGGREGATION AND DISAGGREGATION OF HUMAN AMYLOID β (A) PEPTIDE IN YEAST SYSTEM | 2004 |
|
RU2294964C2 |
| PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF ALZHEIMER-TYPE DEMENTIA | 2013 |
|
RU2811687C2 |
| ANIMAL MODEL OF ZINC-DEPENDENT AMYLOIDOGENESIS IN ALZHEIMER'S DISEASE | 2021 |
|
RU2781331C1 |
| SAFE AND FUNCTIONAL HUMANIZED ANTIBODIES | 2011 |
|
RU2607368C2 |
| BETA-AMYLOID ANTIBODIES | 2013 |
|
RU2689674C2 |
| PEPTIDE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE | 2018 |
|
RU2679059C1 |
| 4-(3-((2-ADAMANTYL)AMINO)-3-OXOPROP-1-EN-1-YL)-N-HYDROXYBENZAMIDE - A NEW DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | 2022 |
|
RU2783995C1 |
